Review the results of pharmacoeconomic trials of antiplatelet drugs in the treatment of patients with acute coronary syndrome

The purpose of this literature review is to systematize and synthesis of the available data for the period 20132016 years of pharmacoeconomics evaluation on the application of modern antiplatelet agents in patients with acute coronary syndrome (ACS). Methods. We conduced search in PubMed system and RNITS keywords «pharmacoeconomis and ticagrelor», «cost-effectiveness and ticagrelor», «budget impact analysis and ticagrelor», «analysis and ticagrelor», «pharmacoeconomics and ticagrelor». The review considered approaches to modelling, identifying the main cost and performance criteria. Results. Based on our analysis of published from 2013 to 2016 years literature, it can be concluded that use of ticagrelor instead of clopidogrel in patients with ACS is the dominant technology in the world and Russian practice. The subject of the comparison is most often (81%) spoke of generic clopidogrel and the entire cohort of patients with ACS, without division into tactics of treatment (81%). In the structure of the published studies pharmacoeconomic prevails (95%) temporary retrospective focus of research with a long time horizon (more than 1 year - 88% of foreign studies). In conducting research using Markov modelling in 71% of cases and the analysis of «cost-effectiveness», 52% of researchers, all of them foreign, further analysed the «cost-utility». The cost analysis of 62% of the authors consider only direct medical costs account for 19% of direct medical costs and indirect costs. The main feature is the inclusion of Russian studies in the analysis of indirect costs is that foreign researchers are doing much less (only 17% of researchers). Conclusion. The analysis of pharmacoeconomic studies of ticagrelor can be recommended as a cost-effective method for the treatment of ACS patients, regardless of treatment strategy.

фармакоэкономика, обзор публикаций, тикагрелор, клопидогрел, острый коронарный синдром, pharmacoeconomics, review, ticagrelor, clopidogrel, acute coronary syndrome

1. Levine G.N., Bates E.R., Blankenship J.C. et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011; 58 (24):e44-122.

2. Weintraub W.S., Mandel L., Weiss S.A. Antiplatelet therapy in patients undergoing percutaneous coronary intervention: economic considerations. // Pharmacoeconomics. 2013 Nov; 31 (11): 959-970.

3. Mahoney E.M., Chu H. Cost-effectiveness analysis alongside clinical trials: statistical and methodological issues. In: Weintraub WS, editor. Cardiovascular Health Care Economics. Totowa: Humana Press; 2003. pp. 123-56.

4. Kazi D.S., Hlatky M.A. A delicate balance: the cost effectiveness of new antiplatelet agents. // JACC (Journal of the American College of Cardiology), 201502-10; 65: 5: 477-479. doi: 10.1016/j.jacc.2014.11.033.

5. James S.K., Roe M.T., Cannon C.P. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ. 2011; 342: d3527.

6. Wallentin L., Becker R.C., Budaj A., Cannon C.P., Emanuelsson H., Held C., Horrow J., Husted S., James S., Katus H., Mahaffey K.W., Scirica B.M., Skene A., Steg P.G., Storey R.F., Harrington R.A.; PLATO Investigators, Freij A., Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009 Sep 10; 361 (11): 1045-57. DOI: 10.1056/NEJMoa0904327.

7. Mejia A., Senior J.M., Ceballos M., Atehortüa S., Toro J.M., Saldarriaga C., Mejia M.E., Ramirez C. Cost-effectiveness analysis of ticagrelor compared to clopidogrel for the treatment of patients with acute coronary syndrome in Colombia. Biomedica. 2015 Oct-Dec; 35 (4): 531-40. doi: 10.7705/biomedica. v35i4.2620.

8. Abdel-Qadir H., Roifman I., Wijeysundera H.C. Cost-effectiveness of clopidogrel, prasugrel and ticagrelor for dual antiplatelet therapy after acute coronary syndrome: a decision-analytic model. CMAJ Open 2015 Dec 9;3(4):E438-46. doi: 10.9778/cmajo.20150056.

9. Yamwong S., Permsuwan U., Tinmanee S., Sritara P. Long-term cost effectiveness of ticagrelor in patients with acute coronary syndromes in Thailand. Health Econ Rev. 2014 Dec; 4 (1): 17. doi: 10.1186/s13561-014-0017-3.

10. Cowper P.A., Pan W., Anstrom K.J., Kaul P., Wallentin L., Davidson-Ray L., Nikolic E., Janzon M., Levin L.?., Cannon C.P., Harrington R.A., Mark D.B. Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study. JACC (Journal of the American College of Cardiology), 201502-10; 65: 5: 465-476. doi: 10.1016/j.jacc.2014.11.034.

11. Gouveia M., Borges M., Trindade R., Rikner K. Economic evaluation of ticagrelor for secondary prevention following acute coronary syndromes. Rev Port Cardiol. 2015 Jan; 34 (1): 17-25. doi: 10.1016/j.repc.2014.08.004.

12. Capel M., Lopez-Sendon J.L., Heras M., Carrera F.J., Brosa M. Cost Effectiveness Analysis Of Ticagrelor Versus Generic Clopidogrel In The Treatment Of Patients With Acute Coronary Syndrome In Spain. Value in Health, 2014-11-01;17: 7: A491-A491 doi: 10.1016/j.jval.2014.08.1452.

13. Wu D.B., Lee B.S., Lee K.K. Cost-Effectiveness Analysis Of Ticagrelor In Treating Patients With Acute Coronary Syndrome In Hong Kong. Value Health. 2014 Nov; 17 (7): A487. doi: 10.1016/j.jval.2014.08.1430.

14. Janzon M., James S., Cannon C.P., Storey R.F., Mellstr?m C., Nicolau J.C., Wallentin L., Henriksson M. Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy. Heart. 2015 Jan; 101 (2): 119-25. doi: 10.1136/heartjnl-2014-305864.

15. Molina-Cuadrado E., Mateo-Carrasco H., Nieto-Guindo P., Rodriguez-Gomez P. Long-term cost-effectiveness of ticagrelor versus clopidogrel in acute coronary syndrome in Spain. Farm Hosp. 2014 Jul 1; 38 (4): 266-75. doi: 10.7399/fh.2014.38.4.1132.

16. Pawçska J., Macioch T., Perkowski P., Budaj A., Niewada M. Direct healthcare costs and cost-effectiveness of acute coronary syndrome secondary prevention with ticagrelor compared to clopidogrel: economic evaluation from the public payer’s perspective in Poland based on the PLATO trial results. Kardiol Pol. 2014; 72 (9): 823-30. doi: 10.5603/KP.a2014.0106.

17. Henriksson M., Nikolic E., Ohna A., Wallentin L., Janzon M. Ticagrelor treatment in patients with acute coronary syndrome is cost-effective in Sweden and Denmark. Scand Cardiovasc J. 2014 Jun; 48 (3): 138-47. doi: 10.3109/14017431.2014.902494.

18. Grima D.T., Brown S.T., Kamboj L., Bainey K.R., Goeree R., Oh. P., Ramanathan K., Goodman S.G. Cost-effectiveness of ticagrelor versus clopidogrel in patients with acute coronary syndromes in Canada. Clinicoecon Outcomes Res. 2014 Jan 24; 6: 49-62. doi: 10.2147/CEOR.S51052.

19. Gasche D., Ulle T., Meier B., Greiner R.A. Cost-effectiveness of ticagrelor and generic clopidogrel in patients with acute coronary syndrome in Switzerland. Swiss Med Wkly. 2013 Sep 19; 143: w13851. doi: 10.4414/smw.2013.13851.

20. Liew D., De Abreu Louren?o R., Adena M., Chim L., Aylward P. Cost-effectiveness of 12-month treatment with ticagrelor compared with clopidogrel in the management of acute coronary syndromes. Clin Ther. 2013 Aug; 35 (8): 1110-1117.e9. doi: 10.1016/j.clinthera.

21. Chin C.T., Mellstrom C., Chua T.S., Matchar D.B. Lifetime cost-effectiveness analysis of ticagrelor in patients with acute coronary syndromes based on the PLATO trial: a Singapore healthcare perspective. Singapore Med J. 2013 Mar; 54 (3): 169-75.

22. Theidel U., Asseburg C., Giannitsis E., Katus H. Cost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany. Clin Res Cardiol. 2013 Jun; 102 (6): 447-58. doi: 10.1007/s00392-013-0552-7.

23. Nikolic E, Janzon M, Hauch O, Wallentin L, Henriksson M; PLATO Health Economic Substudy Group. Cost-effectiveness of treating acute coronary syndrome patients with ticagrelorfor 12 months: results from the PLATO study. // Eur Heart J. 2013 Jan;34(3):220-8. doi: 10.1093/eurheartj/ehs149.

24. Weintraub W.S, Mandel L, Weiss S.A. Antiplatelet therapy in patients undergoing percutaneous coronary intervention: economic considerations. // Pharmacoeconomics. 2013 Nov;31(11):959-70.

25. Henriksson M, Janzon M. Cost-effectiveness of ticagrelor in acute coronary syndromes. Expert Rev Pharmacoecon Outcomes Res. 2013 Feb; 13 (1): 9-18. doi: 10.1586/erp.12.89.

26. Зырянов С.К., Белоусов Д.Ю., Афанасьева Е.В., Думченко Е.В. Анализ «влияния на бюджет» применения антитромбоцитарной терапии тикагрелором и клопидогрелом у пациентов с острым коронарным синдромом, перенесших операцию коронарного шунтирования. Терапевтический архив. 2016; 9: 39-49.

27. Ягудина Р.И., Куликов А.Ю., Крысанов И.С., Литвиненко М.М.,Морозов А.Л. Особенности методологии фармакоэкономических исследований в условиях здравоохранения Российской Федерации (обзор публикаций за период с 1995 по 2007 гг.) Фармакоэкономика. 2009; 1: 3-6.

28. Белоусов Ю.Б., Андреев Б.В., Афанасьева Е.В., Балыкина Ю.Е., Белоусов Д.Ю., Зырянов С.К., Колбин А.С., Курылёв А.А., Павлыш А.В., Проскурин М.А., Пугач И.М. Оценка медицинских технологий. М.: 2013; 16-37.

29. Пядушкина Е.А., Герасимова К.В., Омельяновский В.В., Авксентьева М.В., Крысанов И.С. Фармакоэкономический анализ применения антитром-боцитарной терапии тикагрелором и клопидогрелем с целью профилактики сосудистых явлений и смерти у пациентов с острым коронарным синдромом. Медицинские технологии. Оценка и выбор. 2012; 4: 10: 35-45.

30. Долотовская П.В., Решетько О.В., Малинова Л.И., Фурман Н.В. Соотношение «затраты-эффективность» клопидогрела и тикагрелора при остром коронарном синдроме с подьёмом сегмента ST в реальной клинической практике. Фармакоэкономика: теория и практика. 2016; 1: 206.

31. Куликов А.Ю. Фармакоэкономический анализ двойной антитромбоцитарной терапии ацетилсалициловой кислотой и тикагрелором у пациентов с острым коронарным синдромом, получающих лечение с применением процедуры чрескожной коронарной васкуляризации. // Фармакоэкономика: теория и практика. 2016; 1: 23-28.

32. Колбин А.С., Курылев А.А., Балыкина Ю.Е., Проскурин М.А. Сравнительный экономический анализ клопидогрела и тикагрелора при остром коронарном синдроме. Качественная клиническая практика. 2012; 2: 2-12.